A Single-Patient Study Using AGS 006

Pancreatic Cancer Clinical Trial

Official title:

A Single-Patient Study Using AGS 006 as an Immunotherapeutic in a Subject With Newly Diagnosed Resectable Pancreatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00664482
• Other study ID #: AGS-006-001
• Status: Completed
• Phase: N/A
• First received: April 21, 2008
• Last updated: January 22, 2013
• Start date: May 2007
• Est. completion date: October 2011

Study information

• Verified date: January 2013
• Source: Argos Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.

Description:

Single-patient, open-label clinical study:

• Events during Pre-Treatment Period:

1. Resection of pancreatic cancer,

2. RNA acquisition from tumor specimen,

3. RNA amplification,

4. Infectious disease testing,

5. Autoimmune disease testing,

6. Two blood draws for immune response monitoring,

7. Production leukapheresis, and

8. Dendritic cell electroporation with RNA and immunotherapeutic production;

• Events during Induction Period:

1. Administer investigative treatment every 2 weeks for a total of five doses, followed by dosing every 4 weeks for a total of four doses,

2. Two Induction Period blood draws (Week 6 and Week 12) for immune response monitoring, and

3. One leukapheresis (Week 14) for immune response monitoring;

• Events during Booster Period:

1. Dose every 3 months until progression or 2 years after first AGS treatment,

2. Potentially, one leukapheresis for immune response monitoring 12 months from the first dose, and

3. One blood draw 2 weeks following dosing at Week 36 (1st booster dose) (approximately Week 38); and,

• Events during study Close-Out:

1. Close-Out upon progression or 28 days following immune response monitoring 2 years after first dose

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A male subject 18 years of age or older with newly diagnosed resectable pancreatic cancer who, in the opinion of the investigator, is suitable for participation in the study will be eligible for inclusion if all of the following criteria apply:

1. Able to abstain from taking prohibited prescription or prohibited non-prescription drugs.

2. Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.

3. Voluntary informed consent given to participate in the study.

Exclusion Criteria:

1. Any serious medical condition such as cardiopulmonary disease, circulatory compromise, hepatic or renal dysfunction, or other illness considered by the investigator to constitute an unwarranted high risk for investigational treatment.

2. Active autoimmune disease including, but not limited to:

3. Active, acute, or chronic clinically significant infections including human immunodeficiency virus (HIV) and viral hepatitis.

4. Known hypersensitivity to dimethyl sulfoxide (DMSO).

5. Body weight less than 30 kg.

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Biological:
• AGS-006
Autologous Therapy for Pancreatic Cancer

Locations

Country	Name	City	State
United States	Rockefeller University	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Argos Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment-emergent changes in vital signs (blood pressure, heart rate, respiratory rate, and body temperature) from baseline values obtained prior to each investigative treatment			Yes
Primary	Incidence of treatment-emergent adverse events graded according to the Common Terminology Criteria for Adverse Events			Yes
Primary	Treatment-emergent adenopathy, tenderness, or inflammation (inguinal and axillary) assessed before and after each dose			Yes
Primary	Treatment-emergent changes in autoimmunity evaluations as measured by clinical signs and symptoms and laboratory assessments at periodic intervals during the Treatment Period.			Yes
Primary	Treatment-emergent changes in localized injection site reactions following each dose			Yes
Secondary	Assessment of progression-free survival (PFS) estimated from the date of subject registration - Standard Response Evaluation Criteria in Solid Tumors (RECIST) definitions of progressive disease (PD) will contribute to estimating the interval for PFS.			No
Secondary	T cell response to RNA-electroporated DCs will be assessed by flow cytometry using blood cells collected according to protocol time and events			No
Secondary	Positive immune response			No
Secondary	Feasibility			No